Extended Data Fig. 8: The Primitive versus Mature axis predicts clinical benefit from Gemtuzumab-Ozogamicin in both adult and pediatric AML.

A) Subgroup analysis of randomized clinical trial ALFA-0701 (n = 192) after stratification by PC2-34. Event-free survival (EFS) and Relapse-free survival (RFS) curves comparing chemotherapy only (Control arm) against chemotherapy + Gemtuzumab-Ozogamicin (GO arm). B) Lack of correlation between CD33 levels by flow cytometry and Primitive versus Mature axis (PC2 and PC2-34 score), evaluated across 23 Toronto PMH AML patients for which both RNA-seq and clinical flow information was available. C) Stratification of ALFA-0701 patients on the basis of both LSC17 and LinClass-7. EFS and RFS for the LinClass-7 Low (Mature > Primitive) and LSC17 Low subgroup (n = 56) is depicted as this was the only group to derive significant benefit from GO treatment. D) Stratification of ALFA-0701 patients on the basis of both LSC17 and PC2-34. EFS and RFS for the PC2-34 High (Mature > Primitive) and LSC17 Low subgroup (n = 54) is depicted as this was the only group to derive significant benefit from GO treatment. E-F) Subgroup analysis of a retrospective cohort of pediatric AML patients treated with either GO (n = 154) or Chemo (n = 91), stratified by the PC2 Primitive versus Mature axis and related gene expression scores. Outcomes are depicted for both overall survival (E) and event-free survival (F).